Curidium Medica PLC announces Result of EGM

London--(Marketwire - March 7, 2008) -

               Curidium Medica plc ("Curidium" or the "Company")

               Circular Posted to Shareholders and Notice of EGM



London, UK, 7 March 2008, Curidium Medica plc, (LSE: CUR) the personalized
medicine company focused on bringing the right drug to the right patient, is
pleased to announce that the resolution proposed to shareholders was passed at
its EGM held today.  Accordingly, the 1 for 30 share consolidation of the
Company's existing ordinary shares will take place at the close of business
today, 7 March 2008 ("Share Consolidation").



The Share Consolidation is conditional upon the new ordinary shares of the
Company being admitted to trading on AIM.  Accordingly, an application has been
made for the admission of the new ordinary shares to trading on AIM.  It is
expected that admission will become effective at 8.00am on 10 March 2008,
whereupon the Share Consolidation will be effective and the ordinary share
capital of the Company will be 18,943,440 ordinary shares with a nominal value
of 3p each.



Apart from the change in nominal value, the new ordinary shares arising on
implementation of the Share Consolidation will have the same rights as to
voting, dividends and return of capital as the existing ordinary shares.



                                      Ends



For further information, please contact:
Gosse B. Bruinsma, M.D. +31 (0)629 046 397
Chairman, Curidium Medica plc



Rob Smith +44 (0)20 7383 5345
Finance Director, Curidium Medica plc



Charlie Cunningham +44 (0)20 7600 1658
JM Finn Capital Markets Ltd



Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics



Notes to Editors



About Curidium Medica plc

Curidium is a personalized medicine company identifying targeted medicines and
companion diagnostics to treat patients more effectively.



Curidium's initial focus on diseases of the Central Nervous System has resulted
in the identification of a blood diagnostic test, PsychINDxTM, which classifies
patients with schizophrenia/bipolar disorder into four subgroups. PsychINDxTM
may have the potential to improve the treatment of patients with schizophrenia/
bipolar disorder.



Many chronic human diseases are heterogeneous and their patient populations
consist of mixed subgroups. Through the use of its proprietary analysis tool,
Homomatrix(R), Curidium aims to reveal different patient subgroups characterized
by distinct underlying disease mechanisms potentially leading to the
identification of:



1.  Diagnostics for better identification and treatment within
    heterogeneous disease populations.

2.  Improved therapies identified through novel drug targets.

3.  Personalized medicines using companion diagnostics and targeted treatments.



Curidium aims to continue to use this approach to improve patient treatments in
a variety of therapeutic areas. Further information on Curidium can be found at
the Company's website: www.curidium.com.



Curidium Medica plc (c) 2002-2008. All rights reserved.
Studio 10, Tiger House, Burton Street, London WC1H 9BY, United Kingdom.
Email: info@curidium.com Tel.: +44 (0)20 7383 5345, Fax: +44 (0)20 7383 2973


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END